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ABSTRACT 
Objective: Curcumin presents poor topical bioavailability when administered orally, which poses a major hurdle in its use as an effective therapy 
for the management of psoriasis. The present study reports the utilization of lipid-polymer hybrid nanoparticles (LPHNPs) for the topical delivery of 
curcumin which can be a potential approach for mitigating psoriasis. 
Methods: Curcumin-loaded LPHNPs were prepared by the emulsification solvent evaporation method and characterized. The optimized Curcumin-
loaded LPHNPs (DLN-3) were further incorporated into 2% Carbopol 940 gels and evaluated for its therapeutic efficacy in the Imiquimod (IMQ)-
induced psoriasis rat model. 
Results: The average particle size, polydispersity index, zeta potential, drug entrapment and loading efficiency for DLN-3 were found to be 200.9 
nm, 0.342,-28.3 mV, 87.40±0.99% and 4.57±0.04%, respectively. FT-IR, DSC and XRD studies confirmed that all the components used for the 
formulation are compatible with each other, whereas SEM and TEM analysis affirmed the spherical shape of LPHNPs with a smooth surface. The in 
vitro drug release studies suggest that curcumin was released from the LPHNPs in a sustained manner over a period of 24 h via super case II 
transport mechanism. Results of in vitro skin permeation study revealed that 38.39±2.67% of curcumin permeated at 12 h across excised pig ear 
skin with a permeation flux of 18.74±3.59 µg/cm2
Conclusion: These results suggest that the developed LPHNPs have a superior ability to improve the skin penetration or accumulation of DLN-3 
within psoriatic skin and offer a potential delivery system for the management of psoriasis. 
/h. Further, in vivo evaluation and histopathological studies demonstrated that NLHG-1 hydrogels 
showed better therapeutic efficacy against the psoriatic skin lesions than the standard marketed gels. 
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INTRODUCTION 
Psoriasis is a consistently recurring, autoimmune, chronic 
inflammatory disorder of the skin that is estimated to affect 
approximately 2-4% of the population in Western countries and 
shows lower prevalence in Asian as well as African countries [1, 2]. 
The main pathological features of psoriasis are multifactorial, 
usually involving hyperplasia of the epidermis, abnormal genetic 
association and dysregulated signal processing of T cells as well as 
an imbalance between inflammatory mediators that promote the 
infiltration of leukocytes [3, 4]. Though major problems associated 
with psoriasis are relapsing and spontaneous remission, which may 
trigger by genetic, environmental and several other factors [5]. As 
there is no complete resolution for psoriasis to date, a stepwise 
strategy to healing is often employed with the initial use of topical 
treatment, act to phototherapy and pharmacotherapy. However, the 
presence of multilayered epidermal barriers of psoriatic skin causes 
hindrance to the entry of drug molecules to the inflamed site, 
resulting in the formation of severe adverse effects [6, 7]. To get 
better therapeutic benefits, several nanoparticles have been widely 
explored for topical drug delivery, including polymeric, lipid, 
metallic, carbon-based and vesicular nanoparticles. These 
nanoparticles are shown to be promising in dermatological disease 
management by boosting drug solubility and bioavailability of 
poorly water-soluble drugs [8-13].  
Nevertheless, single nanoparticles unable to provide these benefits 
at a time and have some common limitations in terms of rapid drug 
diffusion, instability during storage and uncontrolled drug release 
[14-16]. Recently, lipid-polymer hybrid nanoparticles (LPHNPs) 
have gained much attention as their outstanding benefits to resolve 
these problems. This system can take the functions of the lipid and 
polymeric nanoparticles, which comprises two distinct components 
i.e., an innermost hydrophobic polymeric core which encapsulating 
the poorly water-soluble drugs and an outermost lipid layer that act 
as a molecular fence to promote drug retention inside the polymeric 
core. Although for topical application, these hybrid nanoparticles 
have been incorporated into hydrogels, which makes the 
formulation very pertinent to achieving the desired effect [17, 18]. 
Curcumin is a yellow-colored polyphenolic compound obtained from 
the rhizome of the perennial herb Curcuma longa and possesses 
outstanding anticancer properties [19]. Despite the promising 
therapeutic value offered by curcumin, its translation from basic 
research to clinical application is limited due to poor water 
solubility and low bioavailability [20, 21]. Therefore, the present 
study was engineered to develop and characterize the LPHNP based 
hydrogels for the topical delivery of curcumin and compares the in 
vivo anti-psoriatic efficacy with the commercial marketed product in 
hopes of assessing a relatively effective and safe medicine for the 
psoriasis treatment.  
MATERIALS AND METHODS 
Materials 
Curcumin and stearic acid were purchased from Hi-Media 
Laboratories Pvt. Ltd., Mumbai, India. Ethylcellulose was purchased 
from Loba Chemie Pvt. Ltd., Mumbai, India. Polyethylene glycol 400 
and tween 80 were purchased from Sisco Research Laboratories Pvt. 
Ltd., Mumbai, India. Carbopol 934, ethanol and triethanolamine were 
purchased from Research Lab Fine Chem Industries, Mumbai, India. All 
other reagents and chemicals used were of analytical grade. 
Preparation of lipid-polymer hybrid nanoparticles (LPHNPs) 
The LPHNPs were prepared by the emulsification solvent 
evaporation method with slight modifications [22, 23]. Briefly, 
stearic acid and ethyl cellulose were dissolved in 2 ml of ethanol in a 
beaker and curcumin was added into the lipid-polymer (oil) phase. 
Resulting lipid-polymer (oil) phase was added dropwise into 10 ml 
of aqueous phase (1% w/v Tween 80) under continuous stirring at 
15000 rpm for 5 min using a homogenizer (Ultra-Turrax T 25 
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Digital, IKA Germany) and further subjected to sonication at 50-55 
°C using bath sonicator (UCB 30, Spectralab Instruments, India) for 
20 min to agitate particles and collapse air bubbles in the liquid 
medium. The dispersion was then stirred continuously for complete 
evaporation of the organic solvent. Spontaneously, the lipid layer 
was self-assembled around the polymeric core resulting in the 
formation of LPHNPs. The nanoparticle dispersions were 
centrifuged at 10000 rpm for 15 min. The supernatant were 
discarded and the solid mass was washed three times with distilled 
water. Finally, the developed formulations were freeze-dried 
(temperature-80 °C and pressure 0.02 mbar) using lyophilizer (SS1-
LYO, Southern Scientific Lab Instruments, India) with 5% mannitol 
for cryoprotection and stored in an airtight container for further use. 
The blank formulations were prepared without the addition of drugs 
using the same procedure.  
Characterization of LPHNPs 
Particle size, polydispersity index and zeta potential 
The average particle size and polydispersity index of the prepared 
LPHNPs were measured by Dynamic Light Scattering using the 
particle size analyzer (90 Plus, Brookhaven Instruments, USA). The 
zeta potential of the prepared LPHNPs was measured by Zetasizer 
(Nano ZS, Malvern Instruments, UK) to assess the surface charge. In 
every cases, the freeze-dried LPHNPs were dispersed in distilled 
water (0.1% w/v) and subsequently analyzed [24]. 
Drug entrapment and drug loading efficiency 
The drug entrapment and drug loading efficiency of the prepared 
LPHNPs were determined by measuring the concentration of free drug 
in the supernatant when it exposed to high-speed centrifugation. 
Simply, the prepared LPHNPs were subjected to centrifugation (R 8C 
DX, REMI, India) at 12500 rpm for 30 min to get the clear supernatant. 
The supernatant was then diluted with ethanol and the concentration 
of free drug present in the supernatant was determined 
spectrophotometrically at 426 nm using UV-Visible 
Spectrophotometer (UV 1800, Shimadzu, Japan) with respect to blank 
ethanol. The percentage drug entrapment and loading efficiency were 
determined according to the following formulas [25]. 
% Drug Entrapment Ef�iciency =
Total Drug − Free Drug
Total Drug
 ×  100 
% Drug Loading Ef�iciency =
Total Drug − Free Drug
Total Weight of Nanoparticles
 ×  100 
Drug-excipient compatibility studies 
To estimate any type of interaction between the drug and excipients, 
FT-IR, DSC and XRD analysis was done for the drug, polymer, lipid, 
physical mixture and drug-loaded LPHNPs. 
In the FT-IR analysis, pure drug curcumin, ethylcellulose, stearic 
acid, physical mixture and blank LPHNPs and curcumin-loaded 
LPHNPs were placed on the sample holder of the FT-IR 
spectrometer (Alpha, Bruker, Germany). The FT-IR spectrum was 
obtained by scanning in the wavenumber region of 4000-400 cm-1
In the DSC analysis, pure drug curcumin, ethylcellulose, stearic acid, 
physical mixture and blank LPHNPs and curcumin-loaded LPHNPs 
were crimped in standard aluminum pans of the Differential 
Scanning Colorimeter (DSC 4000, Perkin Elmer, USA) and heated 
from 0 to 400 °C at a heating rate of 10 °C per minutes under 
constant purging of dry nitrogen. The DSC analysis was mainly 
performed to investigate the thermal behavior of the various 
samples [27].  
 to 
record characteristics peaks and functional groups of the above 
samples [26].  
In the XRD analysis, the diffraction patterns of pure drug curcumin, 
ethylcellulose, stearic acid, physical mixture and blank LPHNPs and 
curcumin-loaded LPHNPs were recorded by X-Ray Diffractometer 
(Ultima IV, Rigaku, Japan) using Cu anode at a voltage of 40 kV and a 
current of 30 mA. The samples were scanned in the range of 10-80 ° 
diffraction angle with a speed of 2 ° per minute. XRD analysis was carried 
out to know the crystalline structure of the above samples [28]. 
Morphological studies 
The external and internal structure of the prepared LPHNPs was 
examined by scanning electron microscopy (SEM) and transmission 
electron microscopy (TEM). 
For SEM analysis, the LPHNPs were dispersed in distilled water and a 
drop of solution was placed on metal stubs with double adhesive 
carbon-coated tape. The metal stubs were then coated with a layer of 
gold to minimize the surface charging. The coated samples were 
randomly scanned by scanning electron microscope (MultiSEM 505, 
ZEISS, Germany) at an accelerating voltage of 20 kV and photographs 
with various magnifications were captured into a computer [29].  
For TEM analysis, the LPHNPs were dispersed in distilled water and 
a drop of sample solution was placed on the carbon-coated copper 
grid. The grid surface was properly air dried before loaded into the 
specimen holder. The samples were then subsequently scanned by 
transmission electron microscope (JEM 2100, JEOL, USA) operating 
at an accelerating voltage of 200 kV and photographs were captured 
using an advanced CCD camera [30]. 
In vitro drug release studies 
The in vitro drug release study was performed using the dialysis bag 
method to determine the release of curcumin from LPHNPs. Initially, the 
dialysis membrane having a molecular weight cutoff 12000 Da, soaked 
in distilled water and subsequently filled with 2 ml of LPHNPs dispersion 
(equivalent to 1.5 mg of curcumin). The dialysis membrane was then 
immersed in the beaker which containing 70 ml of dissolution medium 
(Acetate buffer pH 4.5+PEG 40%). During the experiment, the 
temperature of the dissolution medium was maintained at 37 °C under 
continuous stirring at 200 rpm using a magnetic stirrer (RCT-B-S022, 
IKA, India). At different time intervals, 3 ml of dissolution medium is 
withdrawn and replaced by the same volume of the fresh medium to 
maintain the sink conditions. The samples were further diluted and the 
amount of curcumin released from LPHNPs was quantified 
spectrophotometrically at 439 nm using UV-Visible Spectrophotometer 
(UV 1800, Shimadzu, Japan) with respect to blank [31, 32]. 
In vitro drug release kinetics 
To interpret the mechanism and kinetics of curcumin release from 
LPHNPs, the in vitro drug release data were fitted into different kinetic 
models like zero-order (cumulative amount of drug released vs. time), 
first-order (log cumulative percentage of drug remaining vs. time), 
Higuchi (cumulative percentage drug release vs. square root of time) 
and Korsmeyer-Peppas (log cumulative percentage drug release vs. 
log time) model. By comparing the obtained R2
Stability studies 
 values of the above 
described model, the best-fit model was selected [33]. 
The stability studies of curcumin-loaded LPHNPs were performed as 
per ICH guidelines for a duration of 3 mo at two different storage 
conditions viz. normal conditions (25±2 °C and 75±5% RH) and 
refrigerated conditions (4±2 °C and 75±5% RH). During the period 
of the entire 3 mo, the curcumin-loaded LPHNPs were analyzed for 
changes in their particle size, polydispersity index and drug 
entrapment efficiency at a definite interval of 0, 30, 45, 60 and 90 d 
to assess the stability of the formulations [34]. 
Preparation of hydrogels containing LPHNPs 
For the preparation of topical hydrogels, curcumin-loaded LPHNPs 
were incorporated into Carbopol 940 gel. Accurately weighed of 
Carbopol 940 polymer was dispersed in a sufficient quantity of 
distilled water and stirred continuously using a magnetic stirrer (RCT-
B-S022, IKA, India) to form a gel-like mass. Now the prepared 
curcumin-loaded LPHNPs were added to the hydrogels and mixed 
properly under constant stirring at 1000 rpm for 5 min. The pH of the 
hydrogels was adjusted to ~6 by dropwise addition of triethanolamine 
solution and subsequently, other ingredients like methylparaben and 
glycerin were added to it that act as a preservative as well as a 
humectant. The prepared LPHNPs-loaded hydrogels (NLHG-1) were 
further allowed to stand overnight to remove entrapped air. Similarly, 
blank hydrogels (BHG-1) were prepared without the addition of 
LPHNPs using the same procedure [35, 36].  
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Characterization of hydrogel formulations 
Physical appearance 
The physical appearance of the prepared hydrogels was checked 
visually using a light microscope (Primo Star, ZEISS, Germany) for 
consistency, color, homogeneity and texture [37]. 
pH measurement 
The pH of the prepared hydrogels were determined using a digital 
pH meter (pHTestr 10, Eutech Instruments, Singapore) at room 
temperature. Simply, 2 g of hydrogels were dispersed in 10 ml of 
distilled water and the electrode of the pH meter was then dipped 
into hydrogel dispersion and reading was noted [38].  
Spreadability measurement  
The spreadability of the prepared hydrogels were determined by 
measuring the spreading diameter of gel between two horizontal 
glass plates (20×20 cm ). Briefly, 1 g of the prepared hydrogels were 
placed in the mid of two glass plates and then a 200 g weight was 
applied on the upper glass plate for 5 min to spread the hydrogels. 
The diameters of the spreaded hydrogels were noted and then the 
top plate was pulled with the help of a string. Time is taken in which 
the upper glass plate separated from the lower glass plate was 
considered as a measure of spreadability. The spreadability was 





Where, S=spreadability, M=weight placed to the upper glass plate, 
L=length of the glass plate and T=time taken to separate the glass 
plates completely from each other. 
Drug content estimation 
To determine the drug content, 1 g of the prepared NLHG-1 
hydrogels were dissolved in 25 ml of ethanol in a 100 ml volumetric 
flask. The volumetric flask was shaken for 2 h in order to get 
complete solubility of the drug and made up the volume 100 ml with 
ethanol. Then the solution was filtered using the Whatman syringe 
filter and after subsequent dilution, curcumin content in the filtrate 
was analyzed spectrophotometrically at 426 nm using UV-Visible 
Spectrophotometer (UV 1800, Shimadzu, Japan) with respect to 
blank ethanol [40].  
In vitro skin permeation studies 
The full-thickness of pig ear skin was used for the skin permeation 
experiments. Fresh pig ears were collected from a local 
slaughterhouse of the Dibrugarh University Market. Initially, pig ears 
were thoroughly washed in running tap water and the hair on the 
skin surface was removed using an electric trimmer (NHT 1065, 
NOVA, India). The subcutaneous fat and other extraneous tissue 
adhering to the dermis were completely removed by using scissors 
and then it was kept in 2M sodium bromide solution for 36 h. After 
that, a full-thickness of skin was taken out and the fat adhering to 
the dermis and cut into appropriate sizes. Finally, the skin was 
rinsed with distilled water and was kept in 0.9% sodium chloride 
solution containing 1% formalin in a refrigerator (033E, Samsung, 
South Korea) at a temperature of-20 °C for further use. 
The in vitro skin permeation through excised pig ear skin was 
performed by Franz diffusion cell. Briefly, the skin was clamped 
between the donor and the receptor chamber of a modified Franz 
diffusion cell (effective diffusion area of 1.77 cm2
The permeation profile of curcumin through excised pig ear skin 
was determined by plotting the amount of drug permeated per unit 
area of skin (μg/cm
) with a stratum 
corneum facing the donor compartment. The receptor chamber was 
then filled with dissolution medium (Acetate buffer pH 4.5 + 40% 
v/v PEG 400) and the temperature of the diffusion cell was 
maintained at 37 °C using a re-circulating water bath. The whole 
setup was placed over a magnetic stirrer (RCT-B-S022, IKA, India) 
with constant stirring at 150 rpm. After that, 1 g of prepared NLHG-1 
hydrogels were gently placed in the donor chamber. At different 
time intervals, 2 ml of dissolution medium is withdrawn from the 
receptor chamber and replaced by the same volume of the fresh 
medium to maintain the sink conditions. The samples were further 
diluted and the amount of curcumin permeated from the NLHG-1 
hydrogels were quantified spectrophotometrically at 439 nm using 
UV-Visible Spectrophotometer (UV 1800, Shimadzu, Japan) with 
respect to blank [41]. 
2
Where C= initial concentration of the drug in the donor 
compartment. 
) vs time. The steady-state flux (Jss) of curcumin 
was calculated from the slope of the plot using linear regression 
analysis and the permeability coefficient (Kp) of the drug through 






At the end of the skin permeation study, the mounted skin was 
removed from the compartments of the modified Franz diffusion cell 
and washed thoroughly with distilled water. The skin was then cut 
into small pieces and put into a stoppered conical flask containing 
10 ml of ethanol and stirred continuously at 200 rpm using a 
magnetic stirrer (RCT-B-S022, IKA, India) for 24 h. After that, skin 
samples were homogenized by using a homogenizer (Ultra-Turrax T 
25 Digital, IKA, India) and then centrifuged at 10000 rpm for 15 min 
to get the clear supernatant. The supernatant was then diluted with 
ethanol and the amount of curcumin retained in the skin was 
quantified spectrophotometrically at 426 nm using UV-Visible 
Spectrophotometer (UV 1800, Shimadzu, Japan) with respect to 
blank ethanol [43]. 
Skin accumulation of LPHNPs by TEM analysis 
After the in vitro permeation study, the skin samples were 
successively collected for TEM analysis. Skin samples were washed 
properly and fixed for 3 h in a solution of 2.5% glutaraldehyde in 
0.1M sodium cacodylate buffer (pH 7.2). The fixed samples were 
washed with 0.1 M sodium cacodylate buffer (pH 7.2) twice for 5 
min and then post-fixed for 1 h at 4 °C with 1% osmium tetroxide 
solution. Post-fixed samples were dehydrated with ethanol and then 
embedded in epoxy resin. The resin embedding samples were placed 
in a desiccator for 30 min to remove any moisture content and 
finally observed under the transmission electron microscope (JEM 
2100, JEOL, USA) operating at an accelerating voltage of 200 kV and 
photographs were captured in several different magnifications [44]. 
In vivo antipsoriatic efficacy  
The in vivo antipsoriatic efficacy of the prepared hydrogels were 
performed using healthy Wister Albino Rats of both sex and 
weighing of 150-200 g. All the rats were randomly divided into four 
groups, each containing three rats. Group I was taken as the positive 
control group (without any infection or treatment), Group II was 
taken as the negative control group (IMQ application and no 
treatment), Group III was taken as the standard group (IMQ 
application and treated with the standard marketed formulation of 
Betamethasone Valerate 0.1% w/w cream, GSK Pharmaceuticals 
Ltd., India) and Group IV was taken as the test group (IMQ 
application and treated with prepared NLHG-1 hydrogels). Before 
the experiment, animals were housed properly in polypropylene 
cages placed in a temperature-controlled environment at 22±3 °C 
under 12 h light and 12 h dark cycle with free access to food and 
water. The experiment in these animals was performed in 
accordance with the protocol approved by the Institutional Animal 
Ethical Committee (IAEC), Dibrugarh University, Dibrugarh, Assam, 
India under Approval No. IAEC/DU/149, Dated. 12/06/2018. 
The psoriatic animal model was developed by the topical application 
of 5% w/w Imiquimod (IMQ) cream (Glenmark Pharmaceuticals 
Ltd., India). Briefly, the dorsal skin of each rat was shaved by using 
an electric trimmer (NHT 1065, NOVA, India) and IMQ cream was 
applied topically to the shaved skin (2.5×2.5 cm2skin area) at an 
interval of 24 h up to 5 d. The induced areas were visually examined 
for symptoms resembling psoriasis such as erythema, scaling, skin 
thickening, infiltration of inflammatory cells as well as hyper-and 
Para-keratosis. After the induction period, all the animals were 
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treated for three weeks with the standard marketed gels and 
prepared NLHG-1 hydrogels once in a day, except the positive and 
negative control group. All the animals were observed at least twice 
daily to check the therapeutic efficacy of prepared hydrogel against 
psoriasis. At the end of the study period, all the rats were sacrificed 
according to the ethical guidelines of Dibrugarh University, India 
and skin samples of treated areas were excised histopathological 
analysis [45, 46]. 
Histopathological studies 
The skin of the sacrificed animals was then subjected to 
histopathological analysis for the confirmation of the treatment 
efficacy of nanoformulations. The skin samples were collected from 
all the respective groups of animals and were fixed in 10% formalin 
fixative for 24 h. Collected skin samples were then processed in a 
tissue processor to remove the formalin content, embedded in 
paraffin wax for fixing and vertical skin sections (4 µm) were taken 
using a microtome. After removing the traces of paraffin, skin 
sections were mounted on the glass slide and stained with 
hematoxylin and eosin (H and E). The mounted specimens were 
finally observed under the light microscope fitted with a camera (BX 
40, Olympus, Japan) and photographs were captured [47]. 
Statistical analysis 
All the experimental data are expressed as mean±SD (n=3) and 
analyzed using one-way ANOVA followed by Dunnett’s post hoc tests 
by GraphPad Prism Version 7.0 statistical software. A value of 
P≤0.05 was considered statistically significant. 
RESULTS AND DISCUSSION 
Preparation and optimization of curcumin-loaded LPHNPs 
The curcumin-loaded LPHNPs were successfully prepared by the 
emulsification solvent evaporation method. In this investigation, 
ethylcellulose was used as an innermost hydrophobic polymeric core 
which encapsulating the anticancer drug curcumin and stearic acid 
was used outermost lipid layer that provides the protective shell over 
the polymeric core (fig. 1). All the ingredients used in the preparation 
of lipid-polymer hybrid nanoparticles were reported as biocompatible, 
biodegradable and safe for clinical purpose [48, 49]. 
  
 
Fig. 1: Schematic representation of LPHNPs formulation process 
 
For optimization purposes, the composition of the formulation was 
varied and several trials has been performed for the preparation of 
blank formulations. All the blank formulations were subjected to the 
characterization on the basis of particle size and polydispersity index 
to assess the effect of the lipid-to-polymer ratio. During optimization, 
it was found that ethylcellulose concentration lower than 20 mg 
rendered the structure of nanoparticles and also chances for low drug 
entrapment, whereas greater than 20 mg or excess amounts of 
polymer concentration produced larger size of nanoparticles, mainly 
due to formation of aggregation, which is further decrease the drug 
release and biostability of formulations [50]. Further, stearic acid 
concentration lower than 5 mg leading to sediment at the bottom of 
the container due to precipitation and coalescence of the polymeric 
core resulting from incomplete lipid layer coverage, whereas greater 
than 5 mg or excess amounts of lipid concentration resulting in the 
formation of thick lipid layers, which is further increasing the particle 
size as well as causing some challenges during drug release [51]. 
Hence, for the preparation of stable nanoformulations, the amount of 
ethylcellulose and stearic acid was fixed at 20 mg and 5 mg, 
respectively, as optimal and chosen for subsequent experiments with 
the addition of varying amounts of the drug. The composition of all the 
formulations is shown in table 1. 
 
Table 1: Formulation design of blank and drug-loaded LPHNPs 
Formulation code Ethyl cellulose (mg) Stearic acid  (mg) Drug (mg) Ethanol (ml) Tween 80 (% w/v) Aqueous phase (ml) 
BN-1 20 5 - 2 1 10 
DLN-1 20 5 2 2 1 10 
DLN-2 20 5 3 2 1 10 
DLN-3 20 5 4 2 1 10 
*BN: Blank LPHNPs, DLN: Drug-loaded LPHNPs. 
 
Characterization of LPHNPs 
Particle size, polydispersity index and zeta potential 
The particle size, polydispersity index and zeta potential are the 
crucial parameters that describe the quality and stability of the 
formulations. All the developed formulations, both blank and drug-
loaded LPHNPs were characterized for particle size, polydispersity 
index and zeta potential and the observed values are shown in table 
2. The average particle size and polydispersity index of the prepared 
LPHNPs were measured by Dynamic Light Scattering using the 
particle size analyzer (90 Plus, Brookhaven Instrument, USA) and 
the zeta potential of the prepared LPHNPs were measured by 
Zetasizer (Nano ZS, Malvern Instruments, UK) (fig. 2). From the 
observation, it was found that particle size, polydispersity index and 
zeta potential were significantly affected by the concentration of 
polymer and lipid as well as the concentration of the drug. The 
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particle size and polydispersity index of DLN-1 to DLN-3 were 
increased with increment amount of the polymer and lipid. During 
the emulsification process, an increase in polymer and lipid 
concentration led to an increase in the viscosity of the organic phase 
leading to the formation of larger nanodroplets at the interface [52, 
53]. The zeta potential measurement suggested that surface of the 
nanoparticles was negatively charged. This is mainly due to the 
presence of negatively charged stearic acid on the nanoparticle 
surface imparts anionic nature to the nanoparticles which confirmed 
that the polymeric core was successfully covered up by the lipid 
layer. The observed value revealed that drug-loaded LPHNPs were 
more stable than the blank since the zeta potential value of 
nanoparticles (˃+30 mV or ˂-30 mV) were considered favorable for 
better colloidal stability of the developed nanoparticles [54]. 
 
 
Fig. 2: Particle size distribution of (A) BN-1, (B) DLN-3 and Zeta potential of (C) BN-1, (D) DLN-3 
 
Drug entrapment and drug loading efficiency 
The drug entrapment and loading efficiency are two important 
parameters for assessing the total amount of drug feed during the 
formulation of nanoparticles. The drug entrapment and loading 
efficiency of all the LPHNPs formulations (DLN-1, DLN-2 and DLN-3) 
were determined using UV-Visible Spectrophotometer (UV 1800, 
Shimadzu, Japan) and the observed results are shown in table 2. From 
the observation, it was found that drug entrapment and loading 
efficiency were drastically decreased as the amount of polymer and lipid 
were increased. This is due to the fact that a higher amount of polymer 
and lipid would produce tinny size droplets with large surface areas, 
such that diffusion of the drug was very fast from the nanoparticles 
leading to the lower drug entrapment and loading efficiency [55]. 
 
Table 2: Characterization of LPHNPs 
Formulation code Particle size (nm) Polydispersity index  Zeta potential (mV) DEE (%) DLE (%) 
BN-1 190.8 0.379 -16.3 - - 
DLN-1 268.1 0.384 -36.7 81.83±0.23 2.37±0.14 
DLN-2 300.1 0.373 -31.5 80.24±0.87 3.52±0.11 
DLN-3 200.9 0.342 -28.3 87.40±0.99 4.57±0.04 
*DEE: Drug entrapment efficiency, DLE: Drug loading efficiency., Data are presented as mean±SD (n=3). 
 
Drug-excipient compatibility studies 
For FT-IR analysis, the characteristic spectrums of the pure drug 
curcumin, ethylcellulose, stearic acid, physical mixture, blank 
LPHNPs (BN-1) and curcumin-loaded LPHNPs (DLN-3) were 
recorded and results are shown in fig. 3. From the FT-IR spectrum, it 
was observed that curcumin (fig. 3A) showed major characteristic 
peaks at 3475.58 cm-1 due to O-H stretching, 2909.05 cm-1due to C-H 
stretching, 1625.9 cm-1 due to C=O stretching, 1499.73 cm-1due to C-
C stretching (aromatics) and 1263.27 cm-1 due to C-O stretching 
[56]. The FT-IR spectrum of ethyl cellulose (fig. 3B) indicates the 
characteristic bands at 3498.62 cm-1 due to O-H stretching, 2917.75 
cm-1 due to C-H stretching, 1697.07 cm-1 due to C=O stretching and 
1373.89 cm-1 due to C-H bending [57]. In the FT-IR spectrum of 
stearic acid (fig. 3C), a characteristics peak was observed at 2912.90 
cm-1 due to O-H stretching, 2845.78 cm-1 due to C-H stretching, 
1694.65 cm-1 due to C=O stretching and 1464.06 cm-1 due to C-H 
bending [58]. The spectrum of the physical mixture (fig. 3D) 
illustrates the characteristic bands of all the individual components 
without any remarkable shift from the normal position. The FT-IR 
spectrum of blank LPHNPs (fig. 3E) indicates the presence of distinct 
bands of both ethyl cellulose (1739.70 cm-1) and stearic acid 
(2861.89 cm-1), which further supports the development of 
formulation. However, in the spectrum of curcumin-loaded LPHNPs 
(fig. 3F), it was seen that curcumin reserved its identity, with a slight 
shift of distinct bands at 1453.91 cm-1 and 1252.80 cm-1
  
, suggesting 
C-C stretching and C-O stretching of the drug in the developed 
formulation, was not observed in the spectrum of blank LPHNPs 
which might be due to the overlapping of identical groups in ethyl 
cellulose and stearic acid [59]. 
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Fig. 3: FT-IR spectrums of (A) Curcumin, (B) Ethylcellulose, (C) Stearic acid, (D) Physical mixture, (E) Blank LPHNPs (BN-1), (F) Curcumin-
loaded LPHNPs (DLN-3) 
 
For DSC analysis, the thermograms of the pure drug curcumin, 
ethylcellulose, stearic acid, physical mixture, blank LPHNPs (BN-1) 
and curcumin-loaded LPHNPs (DLN-3) were recorded and results 
are shown in fig. 4. From the DSC thermogram, it was found that 
curcumin (fig. 4A) exhibits a sharp endothermic peak at 185.22 °C, 
indicating its melting point, respectively [60]. The thermogram of 
the ethylcellulose (fig. 4B) showed an exothermic peak at 187.74 °C, 
which is mainly due to the presence of crystalline domains within an 
amorphous base or semi-crystalline structure of the sample, 
whereas stearic acid (fig. 4C) as a lipid component of formulation 
showed an apparent endothermic peak at 62.28 °C [61, 62]. By 
comparing the DSC thermograms of the physical mixture (fig. 4D) 
and blank LPHNPs (fig. 4E) as well as curcumin-loaded LPHNPs (fig. 
4F), it is clearly seen that both contain similar endothermic peaks. 
However, in the case of a physical mixture, the peaks are more 
prominent and sharper than the thermogram of formulations, which 
is mainly due to some components in the formulation may get 
covered or entrapped by other components. Further, the DSC 
thermogram of prepared curcumin-loaded LPHNPs showed the full 
disappearance of all the characteristics peaks of curcumin except 
those pertaining to ethylcellulose and/or stearic acid, confirms the 
molecular dispersion of the curcumin within the polymeric core of 
hybrid nanoparticles or existed in an amorphous form [63]. 
For XRD analysis, the diffractograms of the pure drug curcumin, 
ethylcellulose, stearic acid, physical mixture, blank LPHNPs (BN-1) 
and curcumin-loaded LPHNPs (DLN-3) were recorded and results 
are shown in fig. 5. From the XRD diffractograms, it was observed 
that the curcumin (fig. 5A) showed a group of sharp peaks in the 
range of 10-30 °, which reflecting its crystalline structure [64]. The 
XRD patterns of ethyl cellulose (fig. 5B) displayed a broad peak at 
20.5°, indicating ethyl cellulose have mostly an amorphous region 
with semi-crystalline properties, whereas the diffractogram of 
stearic acid (fig. 5C) showed a typical diffraction peak at 21.0° and 
24.0° indicating that stearic acid has good crystallization properties 
[65, 66]. The typical crystalline peaks of the curcumin (10°, 15°, 
20.5°, 24° and 30°) are clearly visible in the physical mixture (fig. 
5D), but these characteristics peaks are not apparent in the blank 
LPHNPs (fig. 5E) due to the absence of drug and curcumin-loaded 
LPHNPs (fig. 5F), which supports that curcumin was encapsulated in 
the polymeric core of the LPHNPs or might have undergone 
amorphization during formulation [67]. Therefore, drug excipient 
compatibility studies revealed that all the components used for the 
preparation of hybrid nanoparticles are compatible with each other, 
without producing any types of interactions. 
Morphological studies 
The outer shape and surface morphology of the prepared LPHNPs 
were assessed by SEM analysis and results are shown in fig. 6. The 
SEM photomicrographs of the blank (BN-1) (fig. 6A) and curcumin-
loaded LPHNPs (DLN-3) (fig. 6B) affirmed that the shape of the 
nanoparticles was spherical and slightly pyritohedron with smooth 
surface characteristic and no such difference was observed in the 
morphological properties of nanoparticles due to the presence of the 
drug. Moreover, the SEM photomicrographs also revealed that the 
agglomeration of nanoparticles might be due to the lipidic nature of 
the nanoparticles surface and the drying process at the time of 
sample preparation prior to SEM analysis [68]. 
The internal structure and surface morphology of the prepared 
LPHNPs were further examined by TEM analysis and results are 
shown in fig. 6. TEM photographs of the blank (BN-1) (fig. 6C) and 
curcumin-loaded LPHNPs (DLN-3) (fig. 6D) suggested that the 
prepared nanoparticles were well identified with essentially 
spherical or round shape. As seen in TEM photographs, a relatively 
dense region was observed in the center portion. The probable 
reason is that during TEM analysis, the electrons are pass through 
the specimens like lipid or other materials, but in the case of a 
polymer, the electrons are unable to pass through the polymeric 
layer, as a result, the dense region was observed. This result 
indicates that the polymeric core was properly encapsulated within 
the lipid layers [69]. 
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Fig. 4: DSC thermograms of (A) Curcumin, (B) Ethyl cellulose, (C) Stearic acid, (D) Physical mixture, (E) Blank LPHNPs (BN-1), (F) 
Curcumin-loaded LPHNPs (DLN-3) 
 
 
Fig. 5: X-ray diffractograms of (A) Curcumin, (B) Ethylcellulose, (C) Stearic acid, (D) Physical mixture, (E) Blank LPHNPs (BN-1), (F) 
Curcumin-loaded LPHNPs (DLN-3) 
Das et al. 
Int J App Pharm, Vol 13, Issue 3, 2021, 150-164 
157 
 
Fig. 6: Surface morphology: SEM images of (A) BN-1, (B) DLN-3 and TEM images of (C) BN-1, (D) DLN-3 
 
In vitro drug release studies 
The in vitro release studies of various curcumin-loaded LPHNPs 
formulations (DLN-1, DLN-2 and DLN-3) were performed using the 
dialysis bag method and the release profile of curcumin from the 
prepared LPHNPs are presented in fig. 7. During the experiment, 
40% v/v PEG 400 was added to the phosphate buffer solution pH 
4.5, to improve the water solubility of curcumin in maintaining sink 
condition throughout the drug release study. The drug release data 
revealed that all the formulations DLN-1, DLN-2 and DLN-3 were 
showed maximum drug release as 42.73±0.7, 46.16±1.4 and 
55.37±1.4% up to 24 h, respectively. However, all the formulations 
DLN-1, DLN-2 and DLN-3 were showed an initial burst release of 
32.60±1, 32.81±1.3 and 39.34±3.1% in 12 h period and thereafter 
showed slower sustained drug release. The reason behind the initial 
burst release is attributed that the presence of the drug on the 
surface of nanoparticles which might have got desorbed upon 
contact with the dissolution medium, while the slower and sustained 
release may be attributed to the diffusion of drug molecules through 
the polymer core matrix. This finding was further confirmed that 
successful incorporation of curcumin in the polymeric core of the 
LPHNPs could impactfully sustain the release of curcumin [70, 71]. 
 
 
Fig. 7: In vitro drug release profile of prepared LPHNPs (DLN-1, DLN-2 and DLN-3) in acetate buffer pH 4.5+PEG 400 (40% v/v). Each data 
points are presented as mean±SD (n=3) 
 
In vitro drug release kinetics 
The drug release mechanism of all the curcumin-loaded LPHNPs 
formulations (DLN-1, DLN-2 and DLN-3) was interpreted by 
comparing the obtained correlational coefficient (R2 value) of the 
various kinetic models like zero-order, first-order, Higuchi and 
Korsmeyer-Peppas model with one another by model fitting 
equation (table 3). A close observation of R2 values of all the 
curcumin-loaded LPHNPs formulations (DLN-1, DLN-2 and DLN-3) 
attributed the release kinetic with the Korsmeyer-Peppas model 
with R2 values of 0.975 (DLN-1), 0.973 (DLN-2) and 0.975 (DLN-3). 
The release exponent ‘n’ values are 0.91, 0.89 and 0.90 for DLN-1, 
DLN-2 and DLN-3, respectively, indicating that drug release from 
these formulations follows super case II transport mechanism 
operated by swelling and erosion of the polymer/lipid matrix in the 
dissolution medium [72, 73]. 
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Table 3: Correlational coefficient (R2
Formulation 
) of different kinetic models for interpreting the drug release mechanism 
code 
Zero-order model First-order model Higuchi model Korsmeyer-peppas model 
R K2 R0 K2 R1 K2 RH n 2 
DLN-1 0.855 2.075 0.880 -0.011 0.919 11.713 0.975 0.918 
DLN-2 0.884 2.207 0.912 -0.012 0.919 11.713 0.973 0.897 
DLN-3 0.884 2.644 0.923 -0.016 0.921 14.045 0.975 0.909 
 
Stability studies 
The stability of the prepared curcumin-loaded LPHNPs (DLN-1, 
DLN-2 and DLN-3) were investigated in terms of particle size, 
polydispersity index and drug entrapment efficiency (table 4). 
During the entire study period, it was observed that all the 
formulations were stable with minor variations in particle size and 
polydispersity index, without any significant changes in drug 
entrapment efficiency when stored at normal condition (25±2 °C) 
and refrigerated conditions (4±2 °C) for 90 d. The reason behind 
the slight variations in particle size and polydispersity index is 
that when stored at normal conditions the particle size and 
polydispersity index of the formulations were increased due to 
swelling, aggregation and photolytic degradation of particles. 
However, under refrigerated conditions, the particle size and 
polydispersity index were decreased due to the prevention of 
swelling, aggregation and photolytic degradation, stating better 
stability under these conditions. These results further suggested 
that temperature has a significant impact on LPHNPs properties 
and storage under refrigerated conditions is recommended for 
better stability [74, 75]. 
Preparation of hydrogels containing LPHNPs 
After characterization of all the prepared curcumin-loaded LPHNPs 
(DLN-1, DLN-2 and DLN-3) in terms of particle size, polydispersity 
index, zeta potential, drug entrapment efficiency, drug loading 
efficiency and in vitro drug release profiles, the formulation DLN-3 
with optimum physicochemical properties was selected for the 
preparation of topical hydrogels. The composition of the prepared 
topical hydrogels are shown in table 5. 
  
Table 4: Stability studies of prepared curcumin-loaded LPHNPs (DLN-1, DLN-2 and DLN-3) for 90 d 
Time (d) Formulation code Normal conditions (25±2 °C) Refrigerated conditions (4±2 °C) 
PS (nm) PDI DEE (%) PS (nm) PDI DEE (%) 
 
0 
DLN-1 268.1 0.384 81.83±0.23 268.1 0.384 81.83±0.23 
DLN-2 300.1 0.373 80.24±0.87 300.1 0.373 80.24±0.87 
DLN-3 200.9 0.342 87.40±0.99 200.9 0.342 87.40±0.99 
 
30 
DLN-1 308.5 0.264 80.93±1.20 248.8 0.363 81.37±0.57 
DLN-2 342.5 0.403 80.24±1.30 297.1 0.375 80.40±1.20 
DLN-3 247 0.394 87.80±0.43 167.5 0.341 87.16±0.96 
 
60 
DLN-1 313.4 0.383 79.53±1.59 241.0 0.358 79.30±0.45 
DLN-2 352.2 0.366 82.18±0.74 287.9 0.307 80.51±0.69 
DLN-3 260.7 0.315 89.53±0.80 165.1 0.324 87.30±1.70 
 
90 
DLN-1 346.1 0.400 79.60±1.60 218.1 0.264 78.06±0.83 
DLN-2 368 0.388 81.78±0.78 282.2 0.357 79.88±2.14 
DLN-3 269.2 0.359 90.50±1.20 158.0 0.383 88.76±0.50 
*PS: Particle size, PDI: Polydispersity index, DEE: Drug entrapment efficiency. Data are presented as mean±SD (n=3) 
 
Table 5: Formulation design of blank and LPHNPs-loaded hydrogels 












BHG-1 2 - 5 0.7 q. s. q. s. 
NLHG-1 2 0.1 5 0.7 q. s. q. s. 
*BHG: Blank hydrogels, NLHG: LPHNPs-loaded hydrogels. 
 
Characterization of hydrogel formulations 
The physicochemical properties like physical appearance, pH, 
spreadability and drug content of both blank and LPHNPs-loaded 
hydrogels were studied and results are shown in table 6. 
Physical appearance 
The physical appearance of prepared BHG-1 hydrogels was found to be 
off-white in color whereas, NLHG-1 hydrogels were found to be light 
yellow in color (fig. 8) due to the presence of curcumin with smooth in 
texture, semisolid consistency and highly homogenous nature [76]. 
pH measurement 
The pH of the prepared BHG-1 and NLHG-1 hydrogels were found to 
be 4.90±0.15 and 5.53±0.32, respectively, which indicates that the 
pH of prepared hydrogels was slightly below 6.0 or almost near to 
the skin pH. It is physiologically suitable for topical use and also 
adequate for chemical stability since curcumin is unstable at pH 7.0 
or above. As a result, skin irritation was avoided when topically 
applied on the skin surface [77]. 
Spreadability measurement 
The spreadability of the prepared BHG-1 and NLHG-1 hydrogels 
were found to be 17.54±5.76 g-cm/sec and 20.94±14.52 g-cm/sec, 
respectively. These values suggest that the prepared hydrogels are 
easily spreadable on the skin surface by applying a small amount of 
shear. Moreover, the spreadability is not only exhibiting the 
behavior of the hydrogels but also provides better therapeutic 
efficacy, patient compliance as well as suitability for topical 
administration [78]. 
 
Table 6: Characteristics of blank and LPHNPs-loaded hydrogels 
Gel formulation Physical appearance Homogeneity pH Spreadability  (g-cm/sec) Drug content (%) 
BHG-1 Off white Highly homogenous 4.90±0.15 17.54±5.76 - 
NLHG-1 Light yellow Highly homogenous 5.53±0.32 20.94±14.52 89.92±3.4 
Data are presented as mean±SD (n=3). 
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Fig. 8: Physical appearance of (A) BHG-1 hydrogels at 10X and (B) NLHG-1 hydrogels at 10X 
  
Drug content estimation 
The curcumin content in the prepared NLHG-1 hydrogels was found 
to be 89.92±3.4%, which indicates that drug-loaded LPHNPs were 
uniformly distributed and efficiently mixed in the hydrogels and the 
loss of drug or drug-loaded LPHNPs during formulation processes 
was minimal [79].  
In vitro skin permeation studies 
The in vitro skin permeation study was performed using modified 
Franz diffusion cell and results suggested that prepared NLHG-1 
hydrogels showed better permeation through the excised pig ear 
skin and retained in the skin layers for a prolonged period of time. 
As shown in fig. 9, the amount of curcumin permeated from the 
prepared NLHG-1 hydrogels was found to be sustained 
(38.39±2.67%) over a period of 12 h. Further, steady-state flux (Jss) 
and permeability coefficient (Kp) of the prepared NLHG-1 hydrogels 
were found to be 18.74±3.59 µg/cm2/h and 1.87±0.36×10-2
 
 cm/h, 
respectively, which indicates that the curcumin was significantly 
permeated through the pig ear skin from the NLHG-1 hydrogels. The 
enhanced skin permeation of the curcumin from the NLHG-1 
hydrogels is mainly due to the smaller particle size and increased 
surface area of LPHNPs that interface with skin corneocytes and 
more effectively hydrated by the stratum corneum [80]. After 
investigating the skin permeation profile, the amount of curcumin 
retained in the skin was quantified spectrophotometrically and skin 
deposition of the curcumin in the NLHG-1 hydrogels was found to be 
10.20±1.99 µg/ml, which indicated that the LPHNPs were strictly 
confined in the skin layers and exhibit maximum therapeutic efficacy 
in targeted localized skin area. This accumulation of curcumin in the 
epidermis might be attributed to that the uppermost layer of the 
epidermis i.e., stratum corneum consists of 70% proteins, 15% lipids 
and 15% water and this composition of the epidermis affirm 
retention of intact LPHNPs from which curcumin is released slowly 
in the epidermal site of skin where involving the hyper-proliferation 
of keratinocytes and psoriasis. Hence, observed results manifested 
that NLHG-1 hydrogels were suitable for further in vivo study [81, 
82].
 
Fig. 9: In vitro drug permeation profile of prepared LPHNPs-loaded hydrogels (NLHG-1) employing pig ear skin. Each data points are 
presented as mean±SD (n=3) 
 
Skin accumulation of LPHNPs by TEM analysis 
To further confirm the skin accumulation of LPHNPs, skin samples 
from the in vitro permeation study were subjected to TEM analysis 
and photographs are shown in fig. 10. TEM images clearly revealed 
shape-dependent accumulation of various-shaped LPHNPs in the 
diverse layers of skin (red color dotted circles), indicates their 
penetration via the intercellular pathway. The number of LPHNPs 
observed inside epidermis, dermis and adipose tissues was 
dependent on particle size. As the particle size reduced, the higher 
amount of LPHNPs was found to aggregate in the deeper skin layers 
and eventually could reach the viable dermis. Earlier, Tak YK et al. 
(2015) studied skin penetration of silver nanoparticles (AgNPs) 
through mouse skin and found that AgNPs were permeated via an 
intercellular pathway in a size-dependent manner. In our study, 
LPHNPs accumulation appears to be in a similar way [83]. 
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Fig. 10: TEM images of skin samples from in vitro skin permeation study 
 
In vivo antipsoriatic efficacy  
The in vivo antipsoriatic efficacy of the prepared NLHG-1 hydrogels 
and standard marketed gels were evaluated in healthy Wister albino 
rats using 5% w/w IMQ cream-induced psoriatic animal model (fig. 
11). IMQ is an immune modulator mainly used for the treatment of 
external anogenital warts caused by human papillomaviruses (HPV). 
The topical application of IMQ on wild-type mice back skin was 
reported to induce skin lesions or inflammation that closely resembles 
to human psoriasis [84, 85]. After the induction period, the formation 
of lesions and inflammation over the rats skin were examined visually. 
Initially, all the animals and Group I animals (fig. 11A) showed normal 
skin structure without producing any clinical features of psoriasis-like 
inflammation, but the IMQ-treated rats back skin (Group II) (fig. 11B) 
started to exhibit symptoms of very mild thickening, erythema, 
swelling and scaling between 2-5 d. From day 6 onward, the 
inflammation was noticeable and got gradually increased in severity 
up to day 9 (fig. 11C and fig. 11D). These symptoms significantly 
reduced after topical application (started from day 10) of standard 
marketed gels in Groups III (fig. 11C’) and prepared NLHG-1 hydrogels 
in Group IV (fig. 11D’) for the period of three weeks. The results of the 
visual observation were further indicated that the rats were treated 
with prepared NLHG-1 hydrogels showed a maximum reduction of 
skin lesions, erythema, thickening and inflammation as compared to 
the standard marketed gels, which may be due to better skin 
penetration and accumulation of LPHNPs at the site psoriatic skin as 
well as the sustained release of curcumin for a long duration by the 
LPHNPs. Hence, the therapeutic potency of the prepared NLHG-1 
hydrogels was found to be a magnificent and promising alternative 
formulation for psoriasis treatment [86-88]. 
 
 
Fig. 11: In vivo evaluation of IMQ induced psoriatic skin (A) Positive control group, (B) Negative control group, (C/C׳) Standard group, 
where C is the psoriatic skin and C׳ is the cured skin, (D/D׳) Test group, where D is the psoriatic skin and D׳ is the cured skin 
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Histopathological studies 
Histopathological analysis of the skin samples collected from a 
various group of animals i.e., positive control (Group I), negative 
control (Group II), standard (Group III) and test (Group IV) were 
done to observe the psoriatic features and the efficacy of treatment 
in the recovery of psoriatic skin to normal condition. The H and E 
stained images of collected skin samples from various groups of 
animals are shown in fig. 12. 
In the positive control group (fig. 12A), no abnormal phenotype, 
dermal or epidermal irregularities were observed since this group 
does not treated with any chemicals. When compared to the positive 
control group, the negative control group (IMQ-treated group; fig. 
12B) displayed inflammatory cell infiltration, irregular epidermal 
and subcutaneous tissue thickness due to hyperplasia of basal and 
suprabasal keratinocytes, suggesting the induction of psoriasis [89, 
90]. The above-mentioned clinical features of psoriasis were 
significantly hindered after topical treatment with standard 
marketed gels (standard group; fig. 12C/C’) and NLHG-1 hydrogels 
(test group; fig. 12D/D’). Both the standard marketed gels and 
NLHG-1 hydrogels treated group showed an almost similar 
therapeutic effect, but desirable outcomes were seen in the case of 
NLHG-1 hydrogels treated group, probably due to better skin 
penetration and accumulation of LPHNPs as well as the sustained 




Fig. 12: Histopathological observation of r ats skin via H and E staining (A) Positive control group, (B) Negative control group, (C/ C׳) Standard 
group, where C is the psor iatic skin and C׳ is the cured skin, (D/ D׳) Test group, where D is the psor iatic skin and D׳ is the cured skin 
 
CONCLUSION  
In the present study, LPHNPs-loaded hydrogels (NLHG-1) were 
developed and characterized for topical delivery of curcumin in the 
management of chronic inflammatory skin disorders related to 
psoriasis. The curcumin-loaded LPHNPs were successfully prepared 
by the emulsification solvent evaporation method and the results of 
in vitro characterization, drug-excipient compatibility and 
morphology of the developed LPHNPs were found to be in an 
appropriate range along with good compatibility and surface 
properties. In vitro drug release studies revealed that curcumin was 
released from the matrix of LPHNPs in a sustained manner over a 
period of 24 h via super case II transport mechanism followed by the 
Korsmeyer-Peppas model. Further, curcumin-loaded LPHNPs were 
incorporated into the hydrogel matrix for the topical administration 
of curcumin on IMQ-induced psoriatic skin. The results of in vitro 
skin permeation and skin retention study demonstrated that NLHG-
1 hydrogels could significantly increase the permeation of curcumin 
and accumulation of LPHNPs into the pig ear skin for a prolonged 
period of time. Additionally, in vivo evaluation against IMQ-induced 
psoriasis in rats model and the histopathological study 
demonstrated that NLHG-1 hydrogels displayed better therapeutic 
efficacy as compared to the standard marketed gels by showing 
maximum reduction of skin lesions, erythema, thickening and skin 
inflammation. Therefore, it can be concluded that the prepared 
NLHG-1 hydrogels are a suitable and good alternative carrier for the 
management of various skin diseases like psoriasis. 
ACKNOWLEDGEMENT 
The authors are thankful to the Drug Delivery Research Laboratory 
(DDRL), Department of Pharmaceutical Sciences, Dibrugarh 
University, Dibrugarh, Assam, India, for providing the platform to 
conduct this work. 
COMPLIANCE WITH ETHICAL STANDARDS 
The Institutional Animal Ethical Committee (IAEC) of Dibrugarh 
University, Dibrugarh, Assam, India approved the experimental 
protocol (Approval No. IAEC/DU/149, Dated. 12/06/2018). 
Das et al. 
Int J App Pharm, Vol 13, Issue 3, 2021, 150-164 
162 
FUNDING 
This work was financially supported by All India Council for 
Technical Education (AICTE)-PG Scholarship Scheme and Dibrugarh 
University Research Fellowship (DURF) Program. 
AUTHORS CONTRIBUTIONS 
All authors have contributed equally and approved the final version 
of the manuscript as submitted. 
CONFLICT OF INTERESTS 
The authors declare that they have no conflict of interest. All the 
tables and fig. are self-made and original. 
REFERENCES 
1. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Identification 
and management of psoriasis and associated comorbidity 
(IMPACT) project team. Global epidemiology of psoriasis: a 
systematic review of incidence and prevalence. J Invest 
Dermatol 2013;133:377-85. 
2. Alexis AF, Blackcloud P. Psoriasis in skin of color: 
epidemiology, genetics, clinical presentation, and treatment 
nuances. J Clin Aesthet Dermatol 2014;7:16-24. 
3. Moorchung N, Khullar J, Mani N, Chatterjee M, Vasudevan B, 
Tripathi T. A study of various histopathological features and 
their relevance in the pathogenesis of psoriasis. Indian J 
Dermatol 2013;58:294-8.  
4. Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int 
J Mol Sci 2019;20:1475-502.  
5. Zeng J, Luo S, Huang Y, Lu Q. Critical role of environmental 
factors in the pathogenesis of psoriasis. J Dermatol 
2017;44:863-72.  
6. Su YH, Fang JY. Drug delivery and formulations for the topical 
treatment of psoriasis. Expert Opin Drug Delivery 2008;5:235-49. 
7. Wolf R, Orion E, Ruocco E, Ruocco V. Abnormal epidermal 
barrier in the pathogenesis of psoriasis. Clin Dermatol 
2012;30:323-8. 
8. Fereig SA, El-Zaafarany GM, Arafa MG, Abdel-Mottaleb MMA. 
Tackling the various classes of nano-therapeutics employed in 
topical therapy of psoriasis. Drug Delivery 2020;27:662-80. 
9. Zhang Z, Tsai PC, Ramezanli T, Michniak Kohn BB. Polymeric 
nanoparticles-based topical delivery systems for the treatment 
of dermatological diseases. Wiley Interdiscip Rev Nanomed 
Nanobiotechnol 2013;5:205-18.  
10. Hua S. Lipid-based nano-delivery systems for skin delivery of 
drugs and bioactives. Front Pharmacol 2015;6:1-5. 
11. Niska K, Zielinska E, Radomski MW, Inkielewicz Stepniak I. Metal 
nanoparticles in dermatology and cosmetology: interactions with 
human skin cells. Chem Biol Interact 2018;1:38-51. 
12. Zhang Y, Wu M, Wu M, Zhu J, Zhang X. Multifunctional carbon-
based nanomaterials: applications in biomolecular imaging and 
therapy. ACS Omega 2018;3:9126-45.  
13. Carter P, Narasimhan B, Wang Q. Biocompatible nanoparticles 
and vesicular systems in transdermal drug delivery for various 
skin diseases. Int J Pharm 2019;555:49-62. 
14. Rahman M, Akhter S, Ahmad J, Ahmad MZ, Beg S, Ahmad FJ. 
Nanomedicine-based drug targeting for psoriasis: potentials 
and emerging trends in nanoscale pharmacotherapy. Expert 
Opin Drug Delivery 2015;12:635-52. 
15. Gupta S, Bansal R, Gupta S, Jindal N, Jindal A. Nanocarriers and 
nanoparticles for skin care and dermatological treatments. 
Indian Dermatol Online J 2013;4:267-72.  
16. Tahir N, Madni A, Balasubramanian V, Rehman M, Correia A, 
Kashif PM, et al. Development and optimization of 
methotrexate-loaded lipid-polymer hybrid nanoparticles for 
controlled drug delivery applications. Int J Pharm 
2017;533:156-68. 
17. Zhang L, Chan JM, Gu FX, Rhee JW, Wang AZ, Radovic Moreno 
AF, et al. Self-assembled lipid-polymer hybrid nanoparticles: a 
robust drug delivery platform. ACS Nano 2008;2:1696-702.  
18. Hadinoto K, Sundaresan A, Cheow WS. Lipid-polymer hybrid 
nanoparticles as a new generation therapeutic delivery 
platform: a review. Eur J Pharm Biopharm 2013;85:427-43. 
19. Mbese Z, Khwaza V, Aderibigbe BA. Curcumin and its 
derivatives as potential therapeutic agents in prostate, colon 
and breast cancers. Molecules 2019;24:4386-409.  
20. Kamel AE, Fadel M, Louis D. Curcumin-loaded nanostructured 
lipid carriers prepared using Peceol™ and olive oil in 
photodynamic therapy: development and application in breast 
cancer cell line. Int J Nanomed 2019;14:5073-85.  
21. Kotagale NR, Charde PB, Helonde A, Gupta KR, Umekar MJ, Raut 
NS. Studies on bioavailability enhancement of curcumin. Int J 
Pharm Pharm Sci 2020;12:20-5.  
22. Gajra B, Dalwadi C, Patel R. Formulation and optimization of 
itraconazole polymeric lipid hybrid nanoparticles (Lipomer) 
using box behnken design. Daru 2015;23:3-17.  
23. Bose RJ, Arai Y, Ahn JC, Park H, Lee SH. Influence of cationic lipid 
concentration on properties of lipid-polymer hybrid nanospheres 
for gene delivery. Int J Nanomed 2015;10:5367-82. 
24. Massadeh S, Omer ME, Alterawi A, Ali R, Alanazi FH, Almutairi 
F, et al. Optimized polyethylene glycolylated polymer-lipid 
hybrid nanoparticles as a potential breast cancer treatment. 
Pharmaceutics 2020;12:666-79. 
25. Jain A, Thakur K, Kush P, Jain UK. Docetaxel loaded chitosan 
nanoparticles: formulation, characterization and cytotoxicity 
studies. Int J Biol Macromol 2014;69:546-53. 
26. Thadakapally R, Aafreen A, Aukunuru J, Habibuddin M, Jogala S. 
Preparation and characterization of PEG-albumin-curcumin 
nanoparticles intended to treat breast cancer. Indian J Pharm 
Sci 2016;78:65-72.  
27. Govindaraju R, Karki R, Chandrashekarappa J, Santhanam M, 
Shankar A, Joshi HK, et al. Enhanced water dispersibility of 
curcumin encapsulated in alginate-polysorbate 80 
nanoparticles and bioavailability in healthy human volunteers. 
Pharm Nanotechnol 2019;7:39-56.  
28. Khan MA, Zafaryab M, Mehdi SH, Ahmad I, Rizvi MM. 
Characterization and anti-proliferative activity of curcumin 
loaded chitosan nanoparticles in cervical cancer. Int J Biol 
Macromol 2016;93:242-53. 
29. Alizadeh N, Malakzadeh S. Antioxidant, antibacterial and anti-
cancer activities of β-and γ-CDs/curcumin loaded in chitosan 
nanoparticles. Int J Biol Macromol 2020;147:778-91. 
30. Anand P, Nair HB, Sung B, Kunnumakkara AB, Yadav VR, 
Tekmal RR, et al. Design of curcumin-loaded PLGA 
nanoparticles formulation with enhanced cellular uptake, and 
increased bioactivity in vitro and superior bioavailability in 
vivo. Biochem Pharmacol 2010;79:330-8. 
31. Kumar SS, Mahesh A, Mahadevan S, Mandal AB. Synthesis and 
characterization of curcumin loaded polymer/lipid based 
nanoparticles and evaluation of their antitumor effects on MCF-
7 cells. Biochim Biophys Acta 2014;1840:1913-22. 
32. Behbahani ES, Ghaedi M, Abbaspour M, Rostamizadeh K. 
Optimization and characterization of ultrasound assisted 
preparation of curcumin-loaded solid lipid nanoparticles: 
application of central composite design, thermal analysis and X-ray 
diffraction techniques. Ultrason Sonochem 2017;38:271-80. 
33. Dash S, Murthy PN, Nath LK, Chowdhury P. Kinetic modeling on 
drug release from controlled drug delivery systems. Acta Pol 
Pharm 2010;67:217-23. 
34. Dave V, Sharma S, Yadav RB, Agarwal U. Herbal liposome for 
the topical delivery of ketoconazole for the effective treatment 
of seborrheic dermatitis. Appl Nanosci 2017;7:973-87.  
35. Xu H, Wen Y, Chen S, Zhu L, Feng R, Song Z. Paclitaxel skin 
delivery by micelles-embedded Carbopol 940 hydrogel for local 
therapy of melanoma. Int J Pharm 2020;587:1-11. 
36. Bhalekar MR, Pokharkar V, Madgulkar A, Patil N, Patil N. 
Preparation and evaluation of miconazole nitrate-loaded solid 
lipid nanoparticles for topical delivery. AAPS PharmSciTech 
2009;10:289-96. 
37. Dua K, Pabreja K, Ramana MV. Aceclofenac topical dosage 
forms: in vitro and in vivo characterization. Acta Pharm 
2010;60:467-78.  
38. El-Housiny S, Shams Eldeen MA, El-Attar YA, Salem HA, Attia D, 
Bendas ER, et al. Fluconazole-loaded solid lipid nanoparticles 
topical gel for treatment of pityriasis versicolor: formulation 
and clinical study. Drug Delivery 2018;25:78-90.  
Das et al. 
Int J App Pharm, Vol 13, Issue 3, 2021, 150-164 
163 
39. Rajan R, Vasudevan DT. Effect of permeation enhancers on the 
penetration mechanism of transfersomal gel of ketoconazole. J 
Adv Pharm Technol Res 2012;3:112-6.  
40. Hosadurga RR, Rao SN, Jose J, Rompicharla NC, Shakil M, 
Shashidhara R. Evaluation of the efficacy of 2% curcumin gel in 
the treatment of experimental periodontitis. Pharmacogn Res 
2014;6:326-33.  
41. Shakeel F, Ramadan W, Ahmed MA. Investigation of true 
nanoemulsions for transdermal potential of indomethacin: 
characterization, rheological characteristics, and ex vivo skin 
permeation studies. J Drug Target 2009;17:435-41. 
42. Patel D, Dasgupta S, Dey S, Ramani YR, Ray S, Mazumder B. 
Nanostructured lipid carriers (NLC) based gel for the topical 
delivery of aceclofenac: preparation, characterization, and in 
vivo evaluation. Sci Pharm 2012;80:749-64.  
43. Ruela ALM, Figueiredo EC, Perissinato AG, Lima ACZ, Araujo 
MB, Pereira GR. In vitro evaluation of transdermal nicotine 
delivery systems commercially available in Brazil. Braz J Pharm 
Sci 2013;49:579-88. 
44. Filon FL, Crosera M, Adami G, Bovenzi M, Rossi F, Maina G. 
Human skin penetration of gold nanoparticles through intact 
and damaged skin. Nanotoxicology 2011;5:493-501. 
45. Sun L, Liu Z, Wang L, Cun D, Tong HHY, Yan R, et al. Enhanced 
topical penetration, system exposure and anti-psoriasis activity 
of two particle-sized, curcumin-loaded PLGA nanoparticles in 
hydrogel. J Controlled Release 2017;254:44-54. 
46. Nimisha, Rizvi DA, Fatima Z, Neema, Kaur CD. 
Antipsoriatic and anti-inflammatory studies of Berberis 
aristata extract loaded nanovesicular gels. Pharmacogn 
Mag 2017;13(Suppl 3):S587-94.  
47. Mangalathillam S, Rejinold NS, Nair A, Lakshmanan VK, Nair SV, 
Jayakumar R. Curcumin loaded chitin nanogels for skin cancer 
treatment via the transdermal route. Nanoscale 2012;4:239-50. 
48. Maboos M, Yousuf RI, Shoaib MH, Nasiri I, Hussain T, Ahmed 
HF, et al. Effect of lipid and cellulose based matrix former on 
the release of highly soluble drug from 
extruded/spheronized, sintered and compacted pellets. 
Lipids Health Dis 2018;17:1-17.  
49. Killen BU, Corrigan OI. Effect of soluble filler on drug release 
from stearic acid based compacts. Int J Pharm 2006;316:47-51. 
50. Sharma N, Madan P, Lin S. Effect of process and formulation 
variables on the preparation of parenteral paclitaxel-loaded 
biodegradable polymeric nanoparticles: a co-surfactant study. 
Asian J Pharm Sci 2016;11:404-16. 
51. Yuan Y, Chiba P, Cai T, Callaghan R, Bai L, Cole SPC, et al. 
Fabrication of psoralen-loaded lipid-polymer hybrid 
nanoparticles and their reversal effect on drug resistance of 
cancer cells. Oncol Rep 2018;40:1055-63. 
52. Dave V, Yadav RB, Kushwaha K, Yadav S, Sharma S, Agrawal U. 
Lipid-polymer hybrid nanoparticles: development and 
statistical optimization of norfloxacin for topical drug delivery 
system. Bioact Mater 2017;2:269-80. 
53. Sharma D, Maheshwari D, Philip G, Rana R, Bhatia S, Singh M, et 
al. Formulation and optimization of polymeric nanoparticles for 
intranasal delivery of lorazepam using box-behnken design: in 
vitro and in vivo evaluation. BioMed Res Int 2014;156010:1-14. 
54. Lerata MS, D'Souza S, Sibuyi NRS, Dube A, Meyer M, Samaai T, 
et al. Encapsulation of variabilin in stearic acid solid lipid 
nanoparticles enhances its anticancer activity in vitro. 
Molecules 2020;25:830-41.  
55. Mundargi RC, Shelke NB, Rokhade AP, Patil SA, Aminabhavi TM. 
Formulation and in vitro evaluation of novel starch-based 
tableted microsphere for controlled release of ampicillin. 
Carbohydr Polym 2008;71:42-53. 
56. Rajan SS, Pandian A, Palaniappan T. Curcumin loaded in bovine 
serum albumin-chitosan derived nanoparticles for targeted 
drug delivery. Bull Mater Sci 2016;39:811-7. 
57. Akbari Z, Amanlou M, Karimi Sabet J, Golestani A, Niasar MS. 
Characterization of carbamazepine-loaded solid lipid 
nanoparticles prepared by rapid expansion of supercritical 
solution. Trop J Pharm Res 2014;13:1955-61. 
58. Wu X, Zhang L, Zhang X, Zhu Y, Wu Y, Li Y, et al. Ethyl cellulose 
nanodispersions as stabilizers for oil in water pickering 
emulsions. Sci Rep 2017;7:1-10. 
59. Tahir N, Madni A, Correia A, Rehman M, Balasubramanian V, 
Khan MM, et al. Lipid-polymer hybrid nanoparticles for 
controlled delivery of hydrophilic and lipophilic doxorubicin 
for breast cancer therapy. Int J Nanomed 2019;14:4961-74. 
60. Mathew MS, Vinod K, Jayaram PS, Jayasree RS, Joseph K. 
Improved bioavailability of curcumin in the gliadin-protected 
gold quantum cluster for targeted delivery. ACS Omega 
2009;4:14169-78. 
61. Davidovich Pinhas M, Barbut S Marangoni AG. Physical 
structure and thermal behavior of ethylcellulose. Cellulose 
2014;21:3243-55. 
62. Farboud ES, Nasrollahi SA, Tabbakhi Z. Novel formulation and 
evaluation of a Q10-loaded solid lipid nanoparticle cream: in 
vitro and in vivo studies. Int J Nanomed 2011;6:611-7. 
63. Ishak RAH, Mostafa NM, Kamel AO. Stealth lipid polymer hybrid 
nanoparticles loaded with rutin for effective brain delivery-
comparative study with the gold standard (Tween 80): 
optimization, characterization and biodistribution. Drug 
Delivery 2017;24:1874-90. 
64. Wang W, Zhu R, Xie Q, Li A, Xiao Y, Li K, et al. Enhanced 
bioavailability and efficiency of curcumin for the treatment of 
asthma by its formulation in solid lipid nanoparticles. Int J 
Nanomed 2012;7:3667-77.  
65. Mahnaj T, Ahmed SU, Plakogiannis FM. Characterization of 
ethyl cellulose polymer. Pharm Dev Technol 2013;18:982-9. 
66. Wu B, Fu W, Kong B, Hu K, Zhou C, Lei J. Preparation and 
characterization of stearic acid/polyurethane composites as 
dual phase change material for thermal energy storage. J 
Therm Anal Calorim 2018;132:907-17. 
67. Wang W, Chen T, Xu H, Ren B, Cheng X, Qi R, et al. Curcumin-
loaded solid lipid nanoparticles enhanced anticancer efficiency 
in breast cancer. Molecules 2018;23:1578-90. 
68. Mohan DC, Suresh A, Mukundan S, Gupta S, Viswanad V. 
Development and in vitro evaluation of nanolipid carriers of 
clobetasol propionate and pramoxine hydrochloride for topical 
delivery. Int J Appl Pharm 2018;10:28-36. 
69. Tng DJ, Song P, Lin G, Soehartono AM, Yang G, Yang C, et al. 
Synthesis and characterization of multifunctional hybrid-
polymeric nanoparticles for drug delivery and multimodal 
imaging of cancer. Int J Nanomed 2015;10:5771-86. 
70. Jain A, Agarwal A, Majumder S, Lariya N, Khaya A, Agrawal H, et 
al. Mannosylated solid lipid nanoparticles as vectors for site-
specific delivery of an anti-cancer drug. J Controlled Release 
2010;148:359-67. 
71. Wang W, Zhu R, Xie Q, Li A, Xiao Y, Li K, et al. Enhanced 
bioavailability and efficiency of curcumin for the treatment of 
asthma by its formulation in solid lipid nanoparticles. Int J 
Nanomed 2012;7:3667-77.  
72. Das S, Das MK. Synthesis and characterization of thiolated 
jackfruit seed starch as a colonic drug delivery carrier. Int J 
Appl Pharm 2019;11:53-62. 
73. Magesh B, Naidu PY, Rajarajeswar GR. S-adenosyl-l-methionine 
(SAMe)-loaded nanochitosan particles: synthesis, characterisation 
and in vitro drug release studies. J Exp Nanosci 2015;10:828-43. 
74. Lakhani P, Patil A, Taskar P, Ashour E, Majumdar S. Curcumin-
loaded nanostructured lipid carriers for ocular drug delivery: 
design optimization and characterization. J Drug Delivery Sci 
Technol 2018;47:159-66.  
75. Thakkar HP, Patel BV, Thakkar SP. Development and 
characterization of nanosuspensions of olmesartan medoxomil for 
bioavailability enhancement. J Pharm Bioallied Sci 2011;3:426-34. 
76. Vandana D, Pawar S. Formulation and evaluation of topical 
herbal gel containing inclusion complex of curcumin. Asian J 
Pharm Clin Res 2019;12:196-201. 
77. Zamarioli CM, Martins RM, Carvalho EC, Freitas LAP. 
Nanoparticles containing curcuminoids (Curcuma longa): 
development of topical delivery formulation. Rev Bras 
Farmacogn 2015;25:53-60. 
78. Zakaria AS, Afifi SA, Elkhodairy KA. Newly developed topical 
cefotaxime sodium hydrogels: antibacterial activity and in vivo 
evaluation. Biomed Res Int 2016;6525163:1-15.  
79. Fong Yen W, Basri M, Ahmad M, Ismail M. Formulation and 
evaluation of galantamine gel as drug reservoir in transdermal 
patch delivery system. Sci World J 2015;495271:1-7. 
Das et al. 
Int J App Pharm, Vol 13, Issue 3, 2021, 150-164 
164 
80. Rajinikanth PS, Chellian J. Development and evaluation of 
nanostructured lipid carrier-based hydrogel for topical 
delivery of 5-fluorouracil. Int J Nanomed 2016;11:5067-77. 
81. Rapalli VK, Kaul V, Waghule T, Gorantla S, Sharma S, Roy A, et 
al. Curcumin loaded nanostructured lipid carriers for enhanced 
skin retained topical delivery: optimization, scale-up, in vitro 
characterization and assessment of ex-vivo skin deposition. Eur 
J Pharm Sci 2020;152:1-55. 
82. Kesharwani P, Jain A, Srivastava AK, Keshari MK. Systematic 
development and characterization of curcumin-loaded nanogel 
for topical application. Drug Dev Ind Pharm 2020;46:1443-57. 
83. Tak YK, Pal S, Naoghare PK, Rangasamy S, Song JM. Shape-
dependent skin penetration of silver nanoparticles: does it 
really matter? Sci Rep 2015;5:1-11.  
84. Yuan J, Ni G, Wang T, Mounsey K, Cavezza S, Pan X, et al. Genital 
warts treatment: beyond imiquimod. Hum Vaccin Immunother 
2018;14:1815-9. 
85. Seifarth FG, Lax JE, Harvey J, DiCorleto PE, Husni ME, 
Chandrasekharan UM, et al. Topical heat shock protein 70 
prevents imiquimod-induced psoriasis-like inflammation in 
mice. Cell Stress Chaperones 2018;23:1129-35. 
86. Panonnummal R, Jayakumar R, Sabitha M. Comparative anti-
psoriatic efficacy studies of clobetasol loaded chitin nanogel 
and marketed cream. Eur J Pharm Sci 2017;96:193-206. 
87. Sathe P, Saka R, Kommineni N, Raza K, Khan W. Dithranol-
loaded nanostructured lipid carrier-based gel ameliorate 
psoriasis in imiquimod-induced mice psoriatic plaque model. 
Drug Dev Ind Pharm 2020;45:826-38. 
88. Walunj M, Doppalapudi S, Bulbake U, Khan W. Preparation, 
characterization and in vivo evaluation of cyclosporine cationic 
liposomes for the treatment of psoriasis. J Liposome Res 
2020;30:68-79. 
89. Moorchung N, Khullar J, Mani N, Chatterjee M, Vasudevan B, 
Tripathi T. A study of various histopathological features and 
their relevance in pathogenesis of psoriasis. Indian J Dermatol 
2013;58:294-8.  
90. Jia HY, Shi Y, Luo LF, Jiang G, Zhou Q, Xu SZ, et al. Asymmetric 
stem-cell division ensures sustained keratinocyte 
hyperproliferation in psoriatic skin lesions. Int J Mol Med 
2016;37:359-68.  
91. Avasatthi V, Pawar H, Dora CP, Bansod P, Gill MS, Suresh S. A 
novel nanogel formulation of methotrexate for topical 
treatment of psoriasis: optimization, in vitro and in vivo 
evaluation. Pharm Dev Technol 2016;21:554-62. 
92. Khan MA, Pandit J, Sultana Y, Sultana S, Ali A, Aqil M, et al. 
Novel carbopol-based transfersomal gel of 5-fluorouracil for 
skin cancer treatment: in vitro characterization and in vivo 
study. Drug Delivery 2015;22:795-802. 
 
